Document is current
Any future updates will be listed below
-
Authors
Hornfeck, Johannes
Dahlmann, Paul J.
Siegmund, Sophie C.
Gildehaus, Franz J.
Delker, Astrid
Schmidt-Hegemann, Nina-Sophie
Bundschuh, Ralph A.
Zacherl, Mathias J.
Klimek, Konrad
Casuscelli, Jozefina
Stief, Christian G.
Werner, Rudolf A.
Widjaja, Liam https://orcid.org/0000-0002-0243-9338
-
Funding
Funding for this research was provided by:
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 22 December 2025
Accepted: 9 February 2026
First Online: 2 March 2026
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the ethical committee of Ludwig-Maximilians University (#25–0130), which waived the need for informed consent.
: All participants provided informed consent for therapy.
: RAW has received speaker honoraria from and reports advisory board work for Novartis/AAA. RAB is Consultant for and has received speaker´s honoraria from Bayer Healthcare (Leverkusen, Germany), Novartis (Nürnberg, Germany), Terumo GmbH (Eschborn, Germany), and Eisai GmbH (Frankfurt, Germany) and has received travel expenses from Blue Earth Therapeutics (Oxford, UK).
